…on of these biomarkers with the prognosis of patients receiving immune checkpoint inhibitors (ICIs) is not fully understood.Aim and Objectives The objective…
ICIs
This drug is selected. Its supporting articles are shown below.
Articles mentioning ICIs
45 articles · page 1 of 4…Objective Immune checkpoint inhibitors (ICIs) have demonstrated durable clinical benefit in a subset of pati…
…heckpoint inhibitors (ICIs) in lung cancer patients. Currently, ICIs are the most effective treatment for late-stage lung cancer; ho…
…m multiple independent cohorts, including patients treated with ICIs, collected via whole-exome sequencing and targeted sequencing. …
…ogous or allogeneic immune cells (PBMCs, TILs) and treated with ICIs—alone or combined with drugs identified via in silico modeling …
…ell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs) may experience immune-confirmed stable disease (iSD) or progre…
…NSCLC, with no obvious evidence of publication bias.Conclusions Antibiotics and probiotics appear to exert opposite associations with immun…
…The advent of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape of several malig…
…Background Immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) share symptomatic and therapeutic similarities with chro…
…The incorporation of immune checkpoint inhibitors (ICIs) has transformed the management of advanced non-small cell lung…
… cancer (BTC) do not derive durable clinical benefit (DCB) from immune checkpoint inhibitors (ICIs), underscoring the urgent need for predictive biomarkers.…
…Background Immune checkpoint inhibitors (ICIs) enable successful hepatocellular carcinoma (HCC) downstaging o…